Glucose metabolism disorders in the risk factor control in Extremadura Study (COFRE Study);Alteraciones del metabolismo glucídico en el estudio de control de factores de riesgo de Extremadura (estudio COFRE)

Endocrinologia y Nutricion

Volumn 57, Issue 4, 2010, Pages 147-154

  Robles, Nicolás Roberto ^a   Marcos, Gonzalo ^b   Barroso, Sergio ^a   Sánchez Muñoz Torrero, Juan Francisco ^b  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Diabetes mellitus; Dyslipidemia; Hypertension; Impaired fasting glucose

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PULSE PRESSURE; RISK ASSESSMENT; SPAIN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; SMOKING; SPAIN; YOUNG ADULT;

EID: 77951624609     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.01.015     Document Type: Article

References (40)

1. Plan integral de enfermedades cardiovasculares de Extremadura. Mérida. Junta de Extremadura. 2007.
2. Robles N.R., Cid M.C., Roncero F., Pizarro J.L., and Sánchez Casado E. Incidencia de nefropatía diabética en la provincia de Badajoz durante el período 1990-1994. An Med Interna 13 (1996) 572-575
3. Comité de Registro de la SEN Y Registros Autonómicos. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos, año 2000. Nefrología 22 (2002) 310-317
4. Robles N.R., Velasco J., Mena C., Angulo E., Garrote T., and en representación de los investigadores del estudio MICREX. Microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial: estudio de una cohorte de 979 pacientes. Med Clín (Barc) 127 (2006) 761-764
5. Marcos G, Robles NR, Barroso S, Sánchez Muñóz-Torrero JF, en representación de los investigadores del estudio COFRE. Control de la presión arterial en Extremadura: resultados del estudio de control de factores de riesgo en Extremadura (Estudio Cofre). Hipertensión. 2009; 26: 14-19.
6. Marcos G, Robles NR, Barroso S, Sánchez Muñóz-Torrero JF, en representación de los investigadores del estudio COFRE. Control de la dislipemia y uso de hipolipemiantes en Extremadura: resultados del estudio de control de factores de riesgo en Extremadura. Clin Invest Arterioscl. 2009; 21: 56-61.
7. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease: The Framingham Study. JAMA 241 (1979) 2035-2038
8. Baena J.M., Oller M., Martín R., Nicolau M., Altes A., and Iglesias C. Impacto de los nuevos criterios diagnósticos propuestos por la Asociación Americana de Diabetes (ADA-97) sobre la prevalencia diagnóstica de diabetes mellitus tipo 2. Aten Prim 24 (1999) 97-100
9. The Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Report of the committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
10. Keen H. Impact of the new criteria for diabetes on pattern of disease. Lancet 352 (1998) 1000-1001
11. Alberti K.G.M.M., Zimmet P.Z., and for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of WHO consultation. Diabetes Med 15 (1998) 539-553
12. Marín R., De la Sierra A., Armario P., Campos C., Banegas J.R., Gorostidi M., and en representación de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España, 2005. Med Clin (Barc) 125 (2005) 24-34
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26:S5-20.
14. o 02-5215. September 2002.
15. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
16. Van Bortel L.M.A.B., Struijker-Boudier H.A.J., and Safar M.E. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 38 (2001) 914-921
17. García-Puig J., Ruilope L.M., Luque M., Fernández J., Ortega R., Dal-Ré R., and on behalf the AVANT Study Group Investigators. Glucose metabolism in patients with essential hypertension. Am J Med 119 (2006) 318-326
18. Álvarez-Sala L.A., Suárez C., Mantilla T., Franch J., Ruilope L.M., Banegas J.R., et al., en representación deL grupo PREVENCAT. Tratamiento y control del riesgo cardiovascular en Atención Primaria en España. Estudio PREVENCAT. Med Clin (Barc) 124 (2005) 406-410
19. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) of the European Society of Cardiology (ESC). Guidelines for the management of arterial hypertension. J Hypertens 25 (2007) 1105-1187
20. Borch-Johnsen K., Colagiuri S., Balkau B., Glümer C., Carstensen B., Ramachandran A., et al. Creating a pandemic of prediabetes: The proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47 (2004) 1396-1402
21. Engberg S., Vistisen D., Lau C., Glümer C., Jørgensen T., Pedersen O., et al. Progression to impaired glucose regulation and diabetes in the population-based Inter99 study. Diabetes Care 32 (2009) 606-611
22. Su Y., Liu X.M., Sun Y.M., Wang Y.Y., Luan Y., and Wu Y. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. Am J Cardiol 102 (2008) 497-498
23. DECODE Study Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 161 (2001) 397-405
24. Folsom A.R., Szklo M., Stevens J., Liao F., Smith R., and Eckfeldt J.H. A prospective study of coronary heart disease in relation to fasting insulin, glucose and diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care 20 (1997) 935-942
25. The DECODE study group. Glucose tolerance and mortality: Comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354 (1999) 617-621
26. Fisman E.Z., Motro M., Tenenbaum A., Boyko V., Andelzweig L., and Behar S. Impaired fasting glucose concentrations in non-diabetic patients with ischemic heart disease: a marker for worse prognosis. Am Heart J 141 (2001) 485-490
27. Muhlestein J.B., Anderson J.L., Horne B.D., Lavasani F., Allen Maycock C.A., Bair T.L., et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 146 (2003) 351-358
28. Plan de Salud de Extremadura 2009-2012. Mérida. Consejería de Sanidad. Junta de Extremadura. 2009.
29. Mancia G., Grassi G., and Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24 (2006) 3-10
30. Norris K., Bourgoigne J., Gassman J., Hebert L., Middleton J., Phillips R.A., et al., AASK Study Group. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48 (2006) 739-751
31. Lindholm L.H., Persson M., Alaupovic P., Carlberg B., Svensson A., and Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensive: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 (2003) 1563-1574
32. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., Marks R.G., Kowey P., Messerli F.H., et al., INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290 (2003) 2805-2816
33. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363 (2004) 2022-2031
34. The ALLHAT Officers. Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
35. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove N.M., Pressel S.L., Davis B.R., and SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005) 29-35
36. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 369 (2007) 201-207
37. Almgren T., Wilhelmsen L., Samuelsson O., Himmelmann A., Rosengren A., and Anderson O.K. Diabetes in treated hypertension is common and carries a high cardiovascular risk: Results from 20 years follow up. J Hypertens 25 (2007) 1311-1317
38. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove N.M., Pressel S.L., and Pressel S.L. Davis BRLong-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005) 29-35
39. Tranche S., Marín R., Prieto M.A., and Hevia E. La presión de pulso como marcador de riesgo cardiovascular. Hipertensión 18 (2001) 218-224
40. Robles NR, Barroso S, Marcos G, Sánchez Muñóz-Torrero JF, en representación de los investigadores del estudio COFRE. Control de la dislipemia en pacientes diabéticos en Extremadura. Endocrinol Nutr. 2000;56:112-17.